Patents Represented by Attorney, Agent or Law Firm J. Mark Hand
-
Patent number: 6180107Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.Type: GrantFiled: March 10, 1998Date of Patent: January 30, 2001Assignee: Merck & Co., Inc.Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
-
Patent number: 6140073Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.Type: GrantFiled: January 16, 1996Date of Patent: October 31, 2000Assignee: Merck & Co., Inc.Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
-
Patent number: 6054295Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding two human nuclear receptor proteins, designated nNR1, nNR2 and/or nNR2-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR1, nNR2 and/or nNR2-1 activity, and production of antibodies against nNR1, nNR2 and/or nNR2-1, or epitopes thereof.Type: GrantFiled: August 26, 1998Date of Patent: April 25, 2000Assignee: Merck & Co., Inc.Inventor: Fang Chen
-
Patent number: 6031079Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: February 23, 1999Date of Patent: February 29, 2000Assignees: Merck Frosst Canada, Inc., Vanderbilt UniversityInventors: Anthony Ford-Hutchinson, Richard Grygorczyk, Collin Funk, Kathleen Metters
-
Patent number: 6030788Abstract: An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.Type: GrantFiled: February 10, 1999Date of Patent: February 29, 2000Assignee: Merck & Co., Inc.Inventor: David L. Gerhold
-
Patent number: 5994300Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.Type: GrantFiled: September 20, 1993Date of Patent: November 30, 1999Assignee: Merck & Co., Inc.Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
-
Patent number: 5985597Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: May 26, 1993Date of Patent: November 16, 1999Assignees: Merck Frosst Canada, Inc., Vanerbilt UniversityInventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
-
Patent number: 5968800Abstract: An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.Type: GrantFiled: February 5, 1998Date of Patent: October 19, 1999Assignee: Merck & Co., Inc.Inventor: David L. Gerhold
-
Patent number: 5965367Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: September 17, 1997Date of Patent: October 12, 1999Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
-
Patent number: 5958723Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: March 6, 1997Date of Patent: September 28, 1999Assignee: Merck Frosst Canada & Co.Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
-
Patent number: 5932481Abstract: A method for the rapid estimation of hyperplastic and hypertrophic changes in animal airways is an assay which specifically measures acidic and neutral mucoproteins in a linear fashion from 0.5 to at least 10 .mu.g. The assay comprises exposure of a test animal to a suspected metaplastic inducer, removal of the lungs, homogenization in an appropriately buffered solution containing reducing agents and protease inhibitors; removal of particulate matter; and size-fractionation of the SDS treated soluble extract. The high molecular weight material is immobilized and stained for either acidic or neutral mucosubstances and the specific staining is quantitated. The changes observed are consistent with those seen in histological sections of the exposed tissues.Type: GrantFiled: March 23, 1998Date of Patent: August 3, 1999Assignee: Merck Frosst Canada & Co.Inventors: Douglas J. Pon, Louise Boulet, Carlo J. van Staden, Rejean Fortin
-
Patent number: 5869281Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: June 25, 1993Date of Patent: February 9, 1999Assignee: Merck Frosst Canada Inc.Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
-
Patent number: 5866397Abstract: A novel human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This novel PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.Type: GrantFiled: February 14, 1997Date of Patent: February 2, 1999Assignee: Merck & Co., Inc.Inventors: Gideon A. Rodan, Su Jane Rutledge, Azriel Schmidt
-
Patent number: 5861484Abstract: The vascula endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.Type: GrantFiled: January 21, 1997Date of Patent: January 19, 1999Assignee: Merck & Co., Inc.Inventors: Richard L. Kendall, Kenneth A. Thomas, Jr.
-
Patent number: 5840847Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: November 21, 1997Date of Patent: November 24, 1998Assignee: Merck Frosst Canada, Inc.Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
-
Patent number: 5728808Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: August 29, 1995Date of Patent: March 17, 1998Assignee: Merck Frosst Canada, Inc.Inventors: Mark Abramovitz, Yves Bole, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
-
Patent number: 5726152Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.Type: GrantFiled: August 31, 1994Date of Patent: March 10, 1998Assignee: Merck & Co., Inc.Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
-
Patent number: 5719057Abstract: The present invention relates to a stably co-transfected eukaryotic cell line capable of expressing a GABA-A receptor, particularly a human GABA-A receptor, which receptor comprises at least one alpha, one beta and one gamma subunit; to the cloning of novel cDNA sequences encoding the .alpha.-2, .alpha.-3, .alpha.-5, .alpha.-6 and .beta.-2 subunits of the human GABA-A receptor; and to the use of the cell line in designing and developing GABA-A receptor subtype-selective medicaments.Type: GrantFiled: April 5, 1995Date of Patent: February 17, 1998Assignee: Merck Sharpe & Dohme Ltd.Inventors: Karen Louise Hadingham, Beatrice le Bourdelles, Paul John Whiting, Peter Baxter Wingrove
-
Patent number: 5712380Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.Type: GrantFiled: April 21, 1994Date of Patent: January 27, 1998Assignee: Merck & Co., Inc.Inventors: Richard L. Kendall, Kenneth A. Thomas, Jr.
-
Patent number: 5712111Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: April 15, 1994Date of Patent: January 27, 1998Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke